alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsReversible and Irreversible Time-Dependent Behavior of GRCop-84A series of mechanical tests were conducted on a high-conductivity copper alloy, GRCop-84, in order to understand the time dependent response of this material. Tensile, creep, and stress relaxation tests were performed over a wide range of temperatures, strain rates, and stress levels to excite various amounts of time-dependent behavior. At low applied stresses the deformation behavior was found to be fully reversible. Above a certain stress, termed the viscoelastic threshold, irreversible deformation was observed. At these higher stresses the deformation was observed to be viscoplastic. Both reversible and irreversible regions contained time dependent deformation. These experimental data are documented to enable characterization of constitutive models to aid in design of high temperature components.Document ID20170004516Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsLerch, Bradley A.*(NASA Glenn Research Center Cleveland, OH United States)*Arnold, Steven M.*(NASA Glenn Research Center Cleveland, OH United States)*Ellis, David L.*(NASA Glenn Research Center Cleveland, OH United States)*Date AcquiredMay 10, 2017Publication DateApril 1, 2017Subject CategoryStructural MechanicsMetals And Metallic MaterialsReport/Patent NumberGRC-E-DAA-TN31653NASA/TM-2017-219119E-19243Funding Number(s)WBS: WBS 228556.04.03.10Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Keywordsviscoelasticitystress relaxationmechanical propertiesviscoplasticitycopperPoisson ratioplastic deformationcreepconstitutive equationsAvailable DownloadsNameType20170004516.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
I 

118TH CONGRESS 

2D SESSION H. R. 7733 

To amend section 236A of the Immigration and Nationality Act with respect 

to the requirement to cross reference the terrorist screening database. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 19, 2024 

Mr. WILLIAMS of Texas (for himself, Mr. POSEY, Mr. BIGGS, and Mr. JOHNSON of South Dakota) introduced the following bill; which was referred 

to the Committee on the Judiciary 

A BILL 

To amend section 236A of the Immigration and Nationality 

Act with respect to the requirement to cross reference 

the terrorist screening database. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Identifying Potential 

5 Terrorist at the Border Act of 2024’’. 

6 SEC. 2. REQUIREMENT TO REVIEW FEDERAL TERRORIST 

7 SCREENING DATABASE. 

8 Section 236A of the Immigration and Nationality Act 

9 (8 U.S.C. 1226A) is amended— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7733 IH

1 (1) in subsection (a)(3)— 

2 (A) in subparagraph (A), by striking ‘‘; 

3 or’’; 

4 (B) in subparagraph (B), by striking the 

5 period at the end and insert ‘‘; or’’; and 

6 (C) by adding at the end the following: 

7 ‘‘(C) is on the terrorist screening data8 base.’’; and 

9 (2) by adding at the end the following: 

10 ‘‘(d) REQUIREMENT TO REVIEW FEDERAL TER11 RORIST SCREENING DATABASE.—Notwithstanding any 

12 other provision of law, the Commissioner of U.S. Customs 

13 and Border Protection shall take into and maintain cus14 tody over an alien until the Commissioner cross references 

15 the name of such alien with the terrorist screening data16 base and a result for such cross reference is received by 

17 the Commissioner. 

18 ‘‘(e) TERRORIST SCREENING DATABASE DEFINED.— 

19 In this section, the term ‘terrorist screening database’ 

20 shall have the meaning given such term in section 2101 

21 of the Homeland Security Act of 2002.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
§ 876.5880 Isolated kidney perfusion and transport system and accessories. ( a ) *Identification.* An isolated kidney perfusion and transport system and accessories is a device that is used to support a donated or a cadaver kidney and to maintain the organ in a near-normal physiologic state until it is transplanted into a recipient patient. This generic type of device may include tubing, catheters, connectors, an ice storage or freezing container with or without bag or preservatives, pulsatile or nonpulsatile hypothermic isolated organ perfusion apparatus with or without oxygenator, and disposable perfusion set.
( b ) *Classification.* Class II (performance standards).
##### 



EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Great Western Land and Recreation, Inc. (the
Company) for the six months ended March 31, 2005 as filed with the Securities and Exchange
Commission on the date hereof (the Report), I, Jay N. Torok, Principal Financial Officer of
the Company (see explanatory note), certify, pursuant to 18 U.S.C. § 1350, as adopted
pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:  (3)
    The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and(4)
    The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company. /s/ Jay N. Torok
Jay N. Torok
Chairman of the Board and
Principal Financial Officer
July 25, 2005 This certification is made solely for purpose of 18 U.S.C. Section 1350, subject to the knowledge
standard contained therein, and not for any other purpose. This certification is not being filed
as part of this Report or as a separate disclosure document. Explanatory note: Jerome L. Joseph left his position as Chief Financial Officer effective April 25,
2005. Jay N. Torok has been named the Principal Financial Officer for purposes of filing this
report.
<PAGE>

EXHIBIT 99.1

      CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the quarterly report on Form 10-Q of MicroTel
International, Inc. (the "Company") for the quarterly period ended March 31,
2003 (the "Report"), the undersigned hereby certifies in his capacity as Chief
Executive Officer of the Company, pursuant to 18 U.S.C. section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

         1. the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and

         2. the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Dated: May 14, 2003                      By: /s/ CARMINE T. OLIVA
                                            --------------------------------
                                                 Carmine T. Oliva
                                                 Chief Executive Officer

         A signed original of this written statement required by Section 906 has
been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.

                        ---------------------------------

         In connection with the quarterly report on Form 10-Q of MicroTel
International, Inc. (the "Company") for the quarterly period ended March 31,
2003 (the "Report"), the undersigned hereby certifies in his capacity as Chief
Financial Officer of the Company, pursuant to 18 U.S.C. section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

         1. the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and

         2. the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Dated: May 14, 2003                        By: /s/ RANDOLPH D. FOOTE
                                              -------------------------------
                                                   Randolph D. Foote
                                                   Chief Financial Officer

         A signed original of this written statement required by Section 906 has
been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.1240 AC-powered dynamometer. ( a ) *Identification.* An AC-powered dynamometer is an AC-powered device intended for medical purposes to assess neuromuscular function or degree of neuromuscular blockage by measuring, with a force transducer (a device that translates force into electrical impulses), the grip-strength of a patient's hand.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
[52 FR 33702, Sept. 4, 1987, as amended at 84 FR 71818, Dec. 30, 2019]
Michigan Supreme Court Lansing, Michigan

Robert P. Young, Jr.,
Chief Justice

Michael F. Cavanag h Marilyn Kell y Stephen J. Markma n Diane M. Hathawa y Mary Beth Kell y Brian K. Zahra,
J ustices

I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

_______________________________________ __ Clerk March 9, 2011

0302 

# Order

March 9, 2011

141742

PEOPLE OF THE STATE OF MICHIGAN, Plaintiff-Appellee,

v SC: 141742 COA: 289521 Oakland CC: 2007-212928-FH FRANK MICHAEL DRUZYNSKI, Defendant-Appellant.

________________ _______________ __________/

On order of the Court, the application for leave to appeal the July 20, 2010 judgment of the Court of Appeals is consid ered, and it is DENIED, because we are not persuaded that the questions presented should be reviewed by this Court.

M ARILYN 

### K ELLY 

### , J., would grant leave to appeal.
#### State of Connecticut *v.*Roy A. Magoon

Submitted April 30

decided May 7, 1968

*William A. Jacobs,*special public defender, in support of the applications.

The application by the defendant for a stay of execution of the judgment is denied.

The application by the defendant, as amended, for permission to appeal to the Supreme Court of the United States at the expense of the state of Connecticut is denied.
[Nos. 20903-9-II; 21214-5-II.

Division Two.

January 16, 1998.]

#### The State of Washington, *Respondent,*v. Bruce Deyman Price, *Appellant.*

Appeals from judgments of the Superior Court for Pierce County, No. 96-1-00936-1; 96-1-01189-6, Sergio Armijo, J., entered July 11, 1996. *Affirmed*by unpublished opinion per Hunt, J., concurred in by Morgan and Seinfeld, JJ.
**CERTIFICATION**
Each of the undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Vitran CorporationInc., that, to his knowledge, the Annual Report of Vitran Corporation Inc. on Form 10-K for theyear ended December 31, 2004, fully complies with the requirements of Section 13(a) of theSecurities Exchange Act of 1934 and that the information contained in such report fairly presents,in all material respects, the financial condition and results of operation of Vitran CorporationInc.        Date: February 7, 2005      By:  /s/ RICHARD E. GAETZ    Richard E. Gaetz    President and
###### Editorial Note on Part 1

#### Editorial Note:

IRS redesignated the following sections to appear below the undesignated center heading “Regulations Applicable to Certain Bonds Sold Prior to July 8, 1997” and preceding the undesignated center heading “Deductions for Personal Exemptions.” See 62 FR 25507 and 25513, May 9, 1997 for the specific sections involved in the redesignation.

#### §§ 1.148-9A-1.148-10A [Reserved]
UNITED STATES DEPARTMENT OF THE INTERIOR PREPARED ON BEHALF OF THE PROFESSIONAL PAPER 603

GEOLOGICAL SURVEY U.S. ATOMIC ENERGY COMMISSION P 4
LATE
t, a: 58 ae: 2
NORTHWEST rat Top of Ambrosia Dome a5 gi5 oolz5 Aly SIESIE ae EAST
WI Wi Hy W
A ol Base of Dakota Sandstone (flattened) aly alo ® low Blo aloo ale A’
400° z = 400"

GAUIRRREN

| 300"

300°

200° + 200°

Recapture Member
(Base not shown)

|

1 100°

Recapture Member | |
{- ase not shown)

EXPLANATION

Main ore-bearing sandstone mass ss
50

Uranium deposit

Showing approximate outline of material
NORTH containing 0.02 percent or more eU; Og.
B’ Derived mostly from electric drill-hole logs

SOUTH

Z|
ole
Top of Ambrosia Dome Blt
I<
wW
B Base of Dakota Sandstone (flattened) a

BEND IN
SECTION

400'

Claystone and siltstone

+300"

NOTE: Post-Dakota folds are removed.
Based on data available in 1957. Lines
200'~ of sections are shown on figure 6.

I
1
100’ | ,
Recapture Member { Recapture Member. Siltstone and sandstone
I It (Base not shown) {ll {ll | (Base not shown) H
0: \ o i)
Post-Dakota fault
Showing direction of displacement
Main ore-bearing sandstone mass |
Cc — ~ 7
zz zz 2| Ze Zz Drill hole
ae alg Oz ers ale
SOUTH zi6 z|5 Od Ole 8 Z\5 NORTH
wl infu w uy rin ,
c Base of Dakota Sandstone (flattened), alo alo al aoe ale Cc
400° : 400'

Brushy Basin Member.

1 300°

300+

200+ 200'

|_ 100°

eo] Recapture Member

(Base not shown)

Recapture Member
(Base not shown)

GEOLOGIC SECTIONS OF THE MORRISON FORMATION IN THE AMBROSIA LAKE DISTRICT, NORTHWESTERN NEW MEXICO
SHOWING THE BROAD RELATIONS OF THE URANIUM DEPOSITS TO THE MAIN ORE-BEARING SANDSTONE MASS AND TO THE LITHOLOGIC UNITS

6 : f MILES 329-381 O - 69 Plate #4 (In pocket)
L 1 L L

° 1 2 KILOMETERS
L 1 L n | J

VERTICAL EXAGGERATION X10
#### State of Connecticut *v.*Anthony Di Bella et al.

Argued January 2

decided January 30, 1968

*Robert K. Killian,*for the appellant (named defendant).

*Arnold Marhle,*special assistant state’s attorney, for the appellee (state).

The application by Robert K. Killian to withdraw his appearance for the named defendant in the appeal from the Superior Court in New Haven County is granted.
NUREG/BR-0512, Sup. 1
427 A.2d 1225

#### Commonwealth v. Homsher, Jr., Appellant.

Thomas G. Klingensmith, for appellant;

Edward F. Browne, Jr., Assistant District Attorney, for Commonwealth, appellee.

Before PRICE, WIEAND and VAN der VOORT, JJ.*

*

 Judge Donald E. Wieand is sitting by special designation.

Judgment of sentence affirmed.
§ 1.1402(a)-5 Dividends and interest. ( a ) All dividends on shares of stock are excluded unless they are received by an individual in the course of his trade or business as a dealer in stocks or securities.
( b ) Interest on any bond, debenture, note, or certificate, or other evidence of indebtedness, issued with interest coupons or in registered form by any corporation (including one issued by a government or political subdivision thereof) is excluded unless such interest is received in the course of a trade or business as a dealer in stocks or securities. However, interest with respect to which a credit against tax is allowable as provided in section 35, that is, interest on certain obligations of the United States and its instrumentalities, is not included in net earnings from self-employment even though received in the course of a trade or business as a dealer in stocks or securities. Only interest on bonds, debentures, notes, or certificates, or other evidence of indebtedness, issued with interest coupons or in registered form by a corporation, is excluded in the case of all persons other than dealers in stocks or securities; other interest received in the course of any trade or business (such as interest received by a pawnbroker on his loans or interest received by a merchant on his accounts or notes receivable) is not excluded.
( c ) Dividends and interest of the character excludable under paragraphs (a) and (b) of this section received by an individual on stocks or securities held for speculation or investment are excluded whether or not the individual is a dealer in stocks or securities.
( d ) A dealer in stocks or securities is a merchant of stocks or securities with an established place of business, regularly engaged in the business of purchasing stocks or securities and reselling them to customers; that is, he is one who as a merchant buys stocks or securities and sells them to customers with a view to the gains and profits that may be derived therefrom. Persons who buy and sell or hold stocks or securities for investment or speculation, irrespective of whether such buying or selling constitutes the carrying on of a trade or business, are not dealers in stocks or securities.
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.5900 External upper esophageal sphincter compression device. ( a ) *Identification.* An external upper esophageal sphincter compression device is a prescription device used to apply external pressure on the cricoid cartilage for the purpose of reducing the symptoms of laryngopharyngeal reflux disease.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The patient contacting components must be demonstrated to be biocompatible.
( 2 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be demonstrated: ( i ) Mechanical integrity testing (*e.g.,* tensile strength testing, fatigue testing) and
( ii ) Shelf life testing.
( 3 ) The technical specifications must include pressure measurement accuracy to characterize device performance.
( 4 ) Clinical performance testing must document any adverse events observed during clinical use, and demonstrate that the device performs as intended under anticipated conditions of use.
( 5 ) Labeling must include the following: ( i ) Appropriate warnings and precautions,
( ii ) A detailed summary of the clinical testing pertinent to use of the device including a detailed summary of the device-related complications or adverse events,
( iii ) Detailed instructions on how to fit the device to the patient, and
( iv ) Instructions for reprocessing of any reusable components.
( 6 ) Patient labeling must be provided and must include: ( i ) Relevant warnings, precautions, and adverse effects/complications,
( ii ) Information on how to correctly wear the device,
( iii ) The potential risks and benefits associated with the use of the device,
( iv ) Alternative treatments, and
( v ) Reprocessing instructions.
[80 FR 46194, Aug. 4, 2015]
I 

118TH CONGRESS 

2D SESSION H. R. 8068 

To amend the Balanced Budget and Emergency Deficit Control Act of 1985 

to exclude resources designated as an emergency requirement or any 

resources provided in supplemental appropriations laws from CBO baseline projections for discretionary appropriations, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 18, 2024 

Mr. GROTHMAN (for himself, Mr. CLOUD, Ms. MACE, Mr. NORMAN, Mr. 

OGLES, Mr. WEBER of Texas, and Mr. CASE) introduced the following 

bill; which was referred to the Committee on the Budget 

A BILL 

To amend the Balanced Budget and Emergency Deficit Control Act of 1985 to exclude resources designated as an 

emergency requirement or any resources provided in supplemental appropriations laws from CBO baseline projections for discretionary appropriations, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Stop the Baseline 

5 Bloat Act of 2024’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 8068 IH

1 SEC. 2. CHANGES IN THE BASELINE. 

2 Section 257(c) of the Balanced Budget and Emer3 gency Deficit Control Act of 1985 (2 U.S.C. 907(C)) is 

4 amended in the second sentence of paragraph (1) by in5 serting ‘‘excluding resources designated as an emergency 

6 requirement and any resources provided in supplemental 

7 appropriation laws,’’ after ‘‘current year,’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1660 Gonioscopic prism. ( a ) *Identification.* A gonioscopic prism is a device that is a prism intended to be placed on the eye to study the anterior chamber. The device may have angled mirrors to facilitate visualization of anatomical features.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35605, Sept. 14, 1988; 59 FR 63013, Dec. 7, 1994; 66 FR 38812, July 25, 2001]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3200 *Echinococcus* spp. serological reagents. ( a ) *Identification. Echinococcus* spp. serological reagents are devices that consist of *Echinococcus* spp. antigens and antisera used in serological tests to identify antibodies to *Echinococcus* spp. in serum. The identification aids in the diagnosis of echinococcosis, caused by parasitic tapeworms belonging to the genus *Echinococcus* and provides epidemiological information on this disease. Echinococcosis is characterized by the development of cysts in the liver, lung, kidneys, and other organs formed by the larva of the infecting organisms.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 65 FR 2311, Jan. 14, 2000]
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.5830 Implanted diaphragmatic/phrenic nerve stimulator. ( a ) *Identification.* An implanted diaphragmatic/phrenic nerve stimulator is a device that provides electrical stimulation of a patient's phrenic nerve to contract the diaphragm rhythmically and produce breathing in patients who have hypoventilation (a state in which an abnormally low amount of air enters the lungs) caused by brain stem disease, high cervical spinal cord injury, or chronic lung disease. The stimulator consists of an implanted receiver with electrodes that are placed around the patient's phrenic nerve and an external transmitter for transmitting the stimulating pulses across the patient's skin to the implanted receiver.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date premarket approval application (PMA) or notice of completion of a product development protocol (PDP) is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before July 7, 1986 for any implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976, or that has on or before July 7, 1986 been found to be substantially equivalent to an implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976. Any other implanted diaphragmatic/phrenic nerve stimulator shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[44 FR 51730, Sept. 4, 1979, as amended at 51 FR 12101, Apr. 8, 1986]